Back to Agenda
What Question Are You Trying to Answer? The Use of Estimands, Potential Revisions to ICH E-9 and the Impact to Trial Design and Analysis
Session Chair(s)
Thomas J. Permutt, PHD
Associate Director for Statistical Science and Policy, OB, OTS, CDER, FDA, United States
This session will cover the proposed revision to ICH E9 that introduces estimands and their use in answering clinical trial questions, particularly in the case of missing data. Examples of interactions with regulators and the impact on protocols and analysis plans will be discussed.
Learning Objective : Identify the definitions and intended use of estimands.
Speaker(s)
Fanny Ki Wong, PHD
Director and Biometric Team Leader, AstraZeneca, United States
Measuring Effectiveness of Treatment Regimens in Diabetes Clinical Trials
Michael P O'Kelly, PHD, MA
Senior Director, Centre for Statistics in Drug Development, Innovation, QuintilesIMS, Ireland
New Treatment, New Question: Thinking Through the Logic of Estimands
Thomas J. Permutt, PHD
Associate Director for Statistical Science and Policy, OB, OTS, CDER, FDA, United States
Defining Treatment Effects
Have an account?